Paxlovid Is Not Authorized for Longer Than Five Days

In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Seroprevalence of Infection-Induced Antibodies (CDC) 
• Authorization for Vaccine in Young Children Filed (Moderna)
• Public Health Impact of Vaccines in US (BMJ)
• FDA authorizes first approved treatment for children (FDA)
• Phase 2 Data for Sabizabulin (Veru Pharma) 
• Clinical Characteristics of Post Infection Inflammation (The Lancet)
• Fact Sheet for Providers on Evusheld (FDA)
• Fact Sheet for Providers on Paxlovid (FDA)
• Provider Referral for EvuSheld (Northwell Health)
• Contribute to ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 895
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv